Document:

Exhibit 10.74

 

SETTLEMENT AND AMENDMENT AGREEMENT

 

THIS SETTLEMENT AND AMENDMENT
AGREEMENT (this “Agreement”) is made and entered into as of December 31, 2017 (the “Effective
Date”), by and between Cognate BioServices, Inc., a Delaware corporation (“Cognate”) and Northwest
Biotherapeutics, Inc., a Delaware corporation (“NWBio” and together with Cognate, the “Parties”).

 

RECITALS

 

WHEREAS, pursuant
to the existing DCVax®-L and DCVax®-Direct services contracts between NWBio and Cognate (the “Service Contracts”),
NWBio owes or will owe Cognate at least Twenty Five Million, Eight Hundred Forty Three Thousand, Five Hundred and Twenty Four Dollars
($25,843,524) for DCVax programs in 2017 (the “2017 Obligations”);

 

WHEREAS, the Parties
agree to a temporary amendment of the Service Contracts as provided in Section 1.1(c) hereof, under which the amounts due from
NWBio to Cognate under the Contracts are reduced to Twelve Million, Three Hundred Twenty-Two Thousand, Six Hundred Sixty Four ($12,322,664)
for DCVax programs in North America in 2017;

 

WHEREAS, to date,
NWBio has paid Cognate Two Million, Eight Hundred and Two Thousand, Five Hundred Dollars ($2,802,500) for DCVax programs in 2017;
and

 

WHEREAS, on the terms and subject to the
conditions set forth herein, (i) NWBio desires to pay and satisfy the 2017 Obligations through an overall settlement comprised
partly of cash payments, partly of issuance of preferred stock and warrants, and partly of the 2017 Contract Amendments, and (ii)
Cognate is willing to accept such settlement of the 2017 Obligations.

 

AGREEMENT

 

NOW, THEREFORE,
in consideration of the foregoing recitals which are incorporated into and form an integral part of this Agreement, and the mutual
promises, representations, warranties, and covenants set forth herein, and for good and valuable consideration, the receipt and
sufficiency of which the Parties hereby acknowledge the Parties hereby agree as follows:

 

ARTICLE 1

THE TRANSACTION

 

1.1 Settlement of the 2017 Obligations

 

The overall settlement of the 2017 Obligations
shall be comprised of cash payments as provided in Section 1.1(a), issuance of stock and warrants as provided in Section 1.1(b)
and the 2017 Contract Amendments as provided in Section 1.1(c) (collectively, the “Settlement”).

 

    	- 1 -

     

    

 

(a)           Cash
Payment. As of the Effective Date of this Agreement, NWBio already has paid Two Million, Eight Hundred and Two Thousand, Five
Hundred Dollars ($2,802,500) to Cognate in cash (the “Cash Payments”). NWBio will pay the remainder of
Four Million, Five Hundred and Twenty Thousand, One Hundred Sixty Four Dollars ($4,520,164) of the 2017 Obligations to Cognate
to complete the Cash Payments.

 

(b)           Issuance
of Stock and Warrants. NWBio will satisfy Five Million Dollars ($5,000,000) of the 2017 Obligations through issuance of NWBio
Series A convertible preferred stock (the “Series A Preferred Shares”) and warrants (the “Warrants”)
exercisable for common stock (the “Common Shares”) to Cognate or its designee(s) on the same terms as
unrelated investors are purchasing Series A Preferred Shares and Warrants (the “Preferred Stock Financing”),
as set forth in the Summary of the Preferred Stock Financing Terms attached hereto as Exhibit A, the Certificate of Designations
attached hereto as Exhibit B (the “Certificate”) and the form of Warrant (including cashless exercise)
attached hereto as Exhibit C.

 

(c)           2017
Contract Amendments. The Service Contracts are hereby amended to cancel and eliminate charges in excess of Twelve Million,
Three Hundred Twenty-Two Thousand, Six Hundred Sixty Four ($12,322,664) for DCVax programs in North America in 2017 (the “2017
Contract Amendments”). Pursuant to these 2017 Contract Amendments, the remaining Thirteen Million, Five Hundred Twenty
Thousand, Eight Hundred Sixty Dollars ($13,520,860) of 2017 Obligations in excess of the Cash Payments and the Series A Preferred
Shares and Warrants, which would have been owed by NWBio to Cognate for 2017 under the Service Contracts in the absence of the
2017 Contract Amendments, are hereby cancelled and deemed satisfied.

 

(d)           No
Other Amendments. Except as specifically amended by the 2017 Contract Amendments, the terms and conditions of the
Services Contracts remain in full force and effect for DCVax programs in North America.

 

1.2 Fees, Costs and Expenses.

 

NWBio will pay or reimburse
to Cognate all reasonable out-of-pocket costs and expenses incurred by or on behalf of Cognate (including reasonable attorneys’
fees and collection costs), as incurred, in connection with this Agreement, the issuance and receipt of the Preferred Shares, the
Warrants and the Common Shares, and the payment and collection of the Cash Payments.

 

ARTICLE 2

CLOSING DATES; DELIVERY OF PREFERRED SHARES
AND WARRANTS;

COMPLETION OF CASH PAYMENTS AND 2017 CONTRACT
AMENDMENTS

 

2.1 Initial Closing Date; Issuance of Shares and Warrants

 

The closing of the partial satisfaction of 2017
Obligations through issuance of Series A Preferred Shares and Warrants will take place as promptly as practicable following the
closing of the Preferred Stock Financing (the “Initial Closing Date”). On the Initial Closing Date, NWBio will issue
and deliver the Preferred Shares and the Warrants to Cognate or its designee(s).

 

    	- 2 -

     

    

 

2.2 Final Closing Date; Cash Payments and 2017 Contract
Amendment

 

NWBio will use commercially reasonable efforts
to complete the Cash Payments as promptly as practicable following the Initial Closing Date. Within ten (10) business days after
NWBio has completed the Cash Payments, Cognate will undertake such corporate actions as may be necessary to implement or confirm
the 2017 Contract Amendments, and deliver written confirmation of such 2017 Contract Amendments to NWBio. The date upon which such
2017 Contract Amendments are confirmed will be the final closing date.

 

ARTICLE 3

REPRESENTATIONS AND WARRANTIES

 

3.1 NWBio Representations and Warranties.

 

NWBio hereby represents
and warrants to Cognate that as of the date hereof and as of the Closing Date:

 

(a)           NWBio
is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all necessary
corporate power and authority to (i) own, operate and occupy its properties and to carry on its business as presently conducted
and (ii) enter into this Agreement and the other agreements, instruments and documents contemplated hereby, and to consummate the
transactions contemplated hereby and thereby. NWBio is qualified to do business and is in good standing in each jurisdiction in
which the failure to so qualify would have a material adverse effect.

 

(b)           All
necessary corporate proceedings and approvals relating to this Agreement and the transactions contemplated hereunder have been
duly carried out and completed by NWBio. Upon execution, this Agreement will constitute a valid and legally binding obligation
of NWBio, enforceable in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization,
moratorium, and other laws of general application affecting enforcement of creditors’ rights generally, and (ii) as limited
by laws relating to the availability of specific performance, injunctive relief or other equitable remedies.

 

(c)           Upon
issuance hereunder, each Preferred Share and/or Common Share and Common Warrant will be duly authorized, validly issued, fully
paid and non-assessable.

 

3.2 Cognate Representations and Warranties

 

Cognate hereby represents
and warrants to NWBio that as of the date hereof and as of the Closing Date:

 

(a)           Cognate
is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all necessary
corporate power and authority to (i) own, operate and occupy its properties and to carry on its business as presently conducted
and (ii) enter into this Agreement and the other agreements, instruments and documents contemplated hereby, and to consummate the
transactions contemplated hereby and thereby. Cognate is qualified to do business and is in good standing in each jurisdiction
in which the failure to so qualify would have a material adverse effect.

 

    	- 3 -

     

    

 

(b)           All
necessary corporate proceedings and approvals relating to this Agreement and the transactions contemplated hereunder have been
duly carried out and completed by Cognate. Upon execution, this Agreement will constitute a valid and legally binding obligation
of Cognate, enforceable in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization,
moratorium, and other laws of general application affecting enforcement of creditors’ rights generally, and (ii) as limited
by laws relating to the availability of specific performance, injunctive relief or other equitable remedies.

 

(c)           The
Preferred Shares are being acquired by Cognate for investment for Cognate’s own account, not as a nominee or agent, and not
with a view to the resale or distribution of any part thereof except in compliance with applicable securities laws, and Cognate
has no present intention of selling, granting any participation in or otherwise distributing the same except in compliance with
applicable federal and state securities laws.

 

(d)           Cognate
is an “accredited investor” within the meaning of the criteria set forth in Regulation D promulgated
under the Securities Act of 1933.

 

(e)           Cognate
is an experienced investor in securities of companies in the development stage, can bear the economic risk of its investment, including
a total loss, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits
and risks of the investment in the Preferred Shares.

 

ARTICLE 4

MISCELLANEOUS

 

4.1 Governing Law. This Agreement will
be governed by and construed in accordance with the laws of the State of Delaware, without regard to principles or provisions relating
to conflicts of law. The Parties hereby agree that any legal action, suit or proceeding arising out of or relating to this Agreement
will be brought in federal or state court located in the State of Delaware.

 

4.2 Entire Agreement;
Amendments. This Agreement constitutes the full and entire understanding and agreement between the Parties with regard to the
subject thereof. Except as otherwise expressly provided herein, neither this Agreement nor any term hereof or thereof may be amended,
waived, discharged or terminated, except by a written instrument signed by both NWBio and Cognate.

 

4.3 Notices. Any
notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be
in writing, will be effective upon delivery, and may be delivered (a) personally; (b) by email during normal business hours with
confirmation of delivery, provided that a copy is mailed on the next business day by overnight delivery with a nationally recognized
overnight delivery service; or (c) by overnight delivery with a nationally recognized overnight delivery service, in each case
properly addressed to the party to receive the same. The addresses for such communications will be

 

    	- 4 -

     

    

 

in the case of Cognate:

 

Cognate BioServices, Inc.

7513 Connelley Drive, Suite I

Hanover, MD 21076

 

and in the case of NWBio:

 

Northwest Biotherapeutics

4800 Montgomery Lane

Suite 800

Bethesda, MD 20814

 

or at such other address
as the receiving party will have furnished to the sending party in writing.

 

4.4 Survival. Any
right or privilege provided to either Party under this Agreement and all representations and warranties given by the Parties in
this Agreement will survive the delivery of the Preferred Shares under this Agreement until the two year anniversary of the date
that the number of Common Shares sufficient to permit conversion of all of the Preferred Shares becomes available.

 

4.5 Successors and Assigns.
Except as otherwise expressly provided herein, the provisions hereof will be binding upon, and inure to the benefit of, the respective
successors, assigns, heirs, executors and administrators of the Parties hereto. Cognate may transfer or assign all or any portion
of its rights under this Agreement to any person or entity, subject to compliance with applicable securities laws.

 

4.6 No Waiver. Failure
of a Party to exercise any right or remedy under this Agreement or otherwise, or delay by a Party in exercising such right or remedy,
shall not operate or be construed as a waiver thereof. All such rights and remedies shall remain in full force and effect. Failure
of the Parties to implement any transaction contemplated hereunder, or delay by the Parties in implementing any transaction contemplated
hereunder, shall not operate or be construed as a waiver thereof.

 

4.7 Interpretations.
All pronouns and any variations thereof will be deemed to refer to the masculine, feminine, neuter, singular or plural, as the
identity of the person or persons or entity or entities may require. All references to “$” or dollars herein will be
construed to refer to United States dollars. All references to “including” will be construed to mean “including,
without limitation.” The titles of the Sections and subsections of this Agreement are for convenience or reference only and
are not to be considered in construing this Agreement. The language and provisions of this Agreement are the language and provisions
chosen mutually by the Parties hereto, and no doctrine of construction shall be applied for or against any Party.

 

4.8 Severability.
In case any provision of this Agreement is determined to be invalid, illegal or unenforceable, the validity, legality and enforceability
of the remaining provisions will not in any way be affected or impaired thereby, and new provision(s) will be developed and implemented
to achieve as nearly as permitted the substance of the original provision(s).

 

    	- 5 -

     

    

 

4.9 Counterparts.
This Agreement may be executed in counterparts, each of which when so executed and delivered will constitute a complete and original
instrument but all of which together will constitute one and the same agreement, and it will not be necessary when making proof
of this Agreement or any counterpart thereof to account for any counterpart other than the counterpart of the party against whom
enforcement is sought.

 

4.10 WAIVER OF JURY
TRIAL. COGNATE AND NWBIO WAIVE ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING ARISING OUT OF, IN CONNECTION
WITH OR RELATING TO, THIS AGREEMENT AND SECURITIES ISSUED OR ISSUABLE HEREUNDER OR THEREUNDER, AND ANY OTHER TRANSACTION CONTEMPLATED
HEREUNDER OR THEREUNDER. THIS WAIVER APPLIES TO ANY ACTION, SUIT OR PROCEEDING ON ANY BASIS.

 

4.11 No Consequential
Damages. Notwithstanding anything to the contrary, in no event shall any party have any liability for any indirect or consequential
damages or losses, on any basis.

 

4.12 Construction.
The Parties to this Agreement are experienced in sophisticated and complex matters similar to the transactions contemplated by
this Agreement, and this Agreement will be interpreted and construed in a fair and impartial manner without regard to such factors
as which Party prepared the instrument, the relative bargaining powers of the Parties or the domicile of any Party, but shall be
construed and interpreted according to the ordinary meaning of the words used so as to fairly accomplish the purposes and intentions
of both Parties to this Agreement.

 

4.13 Further Assurances.
At any time and from time to time, the Parties will promptly and duly execute and deliver any and all such further instruments
and documents and take such further action as necessary or advisable to enable the Parties to obtain the full benefits of this
Agreement or to exercise any or all rights, remedies and powers pursuant to this Agreement.

 

[SIGNATURE PAGE FOLLOWS]

 

    	- 6 -

     

    

 

IN WITNESS WHEREOF, the Parties
hereto have executed this SETTLEMENT AGREEMENT as of the date set forth in the first paragraph hereof.

 

	 	NORTHWEST BIOTHERAPEIJTICS, INC.
	 	 	 
	 	By:	/s/  Leslie J. Goldman
	 	Name:	Leslie J. Goldman
	 	Title:	Senior Vice President
	 	 
	 	COGNATE BIOSERVICS, INC.
	 	 	 
	 	By:	/s/  J. Kelly Ganjei
	 	Name:	J. Kelly Ganjei
	 	Title:	Chief Executive Officer

 

     

     

    

 

EXHIBIT A

 

SUMMARY OF PREFERRED STOCK FINANCING
TERMS

 

Price per share: $1.70

 

Conversion Ratio: Each share of Series A Preferred Stock
convertible into 10 Common Shares

 

Warrant Coverage: 100%

 

Warrant Exercise Price: $0.22

 

Warrant Exercise Period: 2 yearsExhibit 10.75

 

LOAN AGREEMENT and PROMISSORY NOTE

 

	US $4,000,000	March 14, 2018

 

SECTION 1. GENERAL.

 

Linda F. Powers (the “Holder”)
has granted to Northwest Biotherapeutics, Inc., a Delaware company (the “Maker”) a loan in the principal
amount of Four Million Dollars (US $4,000,000) (the “Loan”) on the terms and conditions set forth in this Loan
Agreement and Promissory Note (the “Note”). The Loan will bear interest from the date the funds are provided by
Holder to Maker until repaid, at a rate of ten percent (10%) per annum (the “Interest”). In addition, warrants
exercisable for common stock of the Maker will be due and issuable to the Holder upon the Holder’s provision of the Loan to Maker
(the “Initial Warrants”), as provided in Section 5. This Note will be payable on demand, in whole or in part, at the
election of the Holder on one or more occasions, with fifteen (15) days’ advance written notice from the Holder to the Maker. Upon
expiration of the notice period (the “Maturity Date”), the Maker will deliver to the Holder, in US dollars in
immediately available funds, at the account notified to Maker by the Holder, payment of the Loan together with all interest thereon
in accordance with the terms hereof (collectively, the “Repayment Amount”) less any amounts which the Holder elects
to convert into equity pursuant to Section 5 hereof.

 

SECTION 2. PRE-PAYMENT.

 

Subject to the Holder’s right to convert
any or all of the Repayment Amount, on one or more occasions, as provided in Section 5 hereof, this Note may be pre-paid in whole
or in part prior to the Maturity Date, at the election of the Maker in its discretion. In such event, the effective date of the
pre-payment shall be deemed to be thrMaturity Date for that portion of the Repayment Amount.

 

SECTION 3. DEFAULT PAYMENT.

 

Upon the occurrence of an Event of Default
(as defined in Section 4 hereof) after notice and one opportunity for cure within five (5) business days after notice thereof,
(“Event of Default”), interest will become payable on all outstanding amounts at a default rate of eighteen percent
(18%) per annum (“Default Interest”) subject to applicable law. Accrual of such Default Interest will commence
upon the occurrence of an Event of Default and will continue until the default is cured, waived or the Repayment Amount is paid
in full.

 

SECTION 4. DEFAULTS.

 

4.1           Definitions.
Each occurrence of any of the following events will constitute an “Event of Default”:

 

     

     

    

 

(a)          if
a default occurs in the payment of any Repayment Amount, or other amounts due under this Note, whether at the due date thereof
or upon acceleration thereof, and such default remains uncured for fifteen (15) business days after written notice thereof from
Holder;

 

(b)          if
any representation or warranty of the Maker made herein will have been false or misleading in any material respect, or will have
contained any material omission, as of the date hereof;

 

(c)          if
a material default occurs in the due observance or performance on the part of the Maker of any covenant or agreement to be observed
or performed pursuant to the terms of this Note and such default remains uncured for ten (10) business days after written notice
thereof from Holder;

 

(d)          if
the Maker (i) discontinues its business, (ii) undergoes a sale of all or substantially all of its assets, reorganization, or direct
or indirect change of effective control, (iii) applies for or consents to the appointment of a receiver, trustee, custodian or
liquidator of Maker or any of its property, (iv) makes a general assignment for the benefit of creditors, or (v) files a voluntary
petition in bankruptcy, or a petition or an answer
seeking reorganization or an arrangement with creditors, or takes advantage of any bankruptcy, reorganization, insolvency, readjustment
of debt, dissolution or liquidation laws or statutes, or file an answer admitting the material allegations of a petition filed
against it in any proceeding under any such law;

 

(e)          if
there is filed against, Maker an involuntary petition seeking reorganization of Maker or the appointment of a receiver, trustee,
custodian or liquidator of Maker or a substantial part of its assets, or an involuntary petition under any bankruptcy, reorganization
or insolvency law of any jurisdiction, whether now or hereafter in effect (any of the foregoing petitions being hereinafter referred
to as an “Involuntary Petition”) and such Involuntary Petition will not have been dismissed within ninety (90)
days after it was filed;

 

4.2           Remedies
on Default. 

 

(a)          Upon
each and every such Event of Default and at any time thereafter during the continuance of such Event of Default: (i) any and all
indebtedness . and related amounts due from the. Maker to the Holder under this Note or otherwise will immediately become due and
payable; (ii) Default Interest will accrue and be payable until all of the foregoing amounts have been paid in full and (iii) the
Holder may exercise all the rights of a creditor under applicable law.

 

(b)          In
the event that any one or more Events of Default will occur and be continuing, and acceleration of this Note or any other indebtedness
or obligation of the Maker to the Holder will have occurred, the Holder may, inter aria,
proceed to protect and enforce its rights by an action at law, suit in equity and/or other
appropriate proceeding.,No right conferred upon the Holder by this Note will be exclusive of any other right referred to herein
or therein or now or hereafter available at law, in equity, by statute or otherwise.

 

    	 	2	 

     

    

 

SECTION 5. CONVERSION AND WARRANTS 

 

5.1           Conversion Election.
Holder will have the right to elect, in its sole discretion, at any time or times on or before the Maturity Date (or such later
date at which the Repayment Amount is repaid in full), to convert all or any part of the Repayment Amount into Series B Preferred
Stock and related warrants (the “Conversion Warrants”), on the terms set forth in this Section 5. The price per share
of the Series B Preferred Stock will be Two Dollars and Thirty Cents ($2.30) per share, with each share of such Preferred Stock
convertible into ten (10) shares of Common Stock (but only upon the earlier of such Common Stock being available for issuance or
June 1, 2018) at an effective price of Twenty-Three Cents ($0.23) per share of Common Stock, and with voting rights equal to ten
(10) votes per share of Series B Preferred Stock.

 

5.2           Warrants.
The Initial Warrants will be exercisable for a number of shares of the Maker’s Common Stock that is equal to fifty percent (50%)
of the number of shares into which the full Repayment Amount would be convertible at a price of Twenty-three Cents ($0.23) per
share. As provided in Section 1, the Initial Warrants become due and payable upon the Holder entering into the Loan. In the event
that the Holder elects to convert all or any part of the Repayment Amount into Series B Preferred Stock (or Common Stock) of the
Maker, the Conversion Warrants will become due and payable on a proportionate basis, up to a number of shares of the Maker’s common
stock that is equal to fifty percent (50%) of the number of shares into which the full Repayment Amount would be convertible at
a price of Twenty-three Cents ($0.23) per share. Both the Initial Warrants and the Conversion Warrants will only become exercisable
upon the earlier of Common Stock bring available for issuance or June 1, 2018. Both the Initial Warrants and the Conversion Warrants
will be exercisable at a price of Thirty Cents ($0.30) per share of Common Stock, will include cashless exercise, and will have
an exercise period of five (5) years from the dates the warrants become exercisable.

 

5.3           Delivery of Conversion Shares and Conversion Warrants. Maker will deliver the Conversion Shares and Conversion Warrants l6
Holder within three (3) business days following delivery of a Conversion Notice to Maker (the “Delivery Date”). Maker
understands that a delay in the delivery of Conversion Shares beyond the applicable Delivery Date could result in economic loss
to Holder. As compensation to Holder for such risk, in addition to any other available remedies at law or equity, Maker agrees
to pay late fees to Holder, for delivery of the Conversion
Shares andWrrants after the Delivery Date, equal to $1,000 per day.

 

5.4           Piggy-Back Registration.
Holder will be entitled to piggy-back registration rights with respect to the Conversion Shares. Maker will bear all reasonable
and customary expenses relating to the preparation and filing of any registrations.

 

SECTION 6. EXTENSION OF MATURITY. .

 

In the event that the
Repayment Amount or any other amounts due under this Note become due and payable on other than a business day, the due date thereof’
(including the Maturity Date) will be extended to the next succeeding business day in the United States. For purposes of the preceding
sentence, a business day will be any day that is not a Saturday or Sunday, or a legal holiday in the State of New York in the United
States.

 

    	 	3	 

     

    

 

SECTION 7. ATTORNEYS’ FEES AND COLLECTION COSTS.

 

In the event that all
or part of the indebtedness evidenced by this Note is collected at law or in equity, or in bankruptcy, receivership or other court
proceedings. arbitration or mediation, or any settlement of any of the foregoing, the Maker agrees to pay, in addition to all amounts
due and payable hereunder, all costs of collection incurred by the Holder in collecting or enforcing this Note, including, without
limitation, reasonable attorneys’ fees and expenses actually incurred.

 

SECTION 8. WAIVERS, DISPUTES, JURISDICTION.

 

8.1           Actions
of Holder not a Waiver. No delay by Holder in exercising any power or right hereunder will operate as a waiver of any
power or right, nor will any single or partial exercise of any power or right preclude other or further exercise thereof, or
the exercise of any other power or right hereunder or otherwise; and no waiver or modification of the terms hereof will be
valid unless set forth in writing by the Holder and then only to the extent set forth therein.

 

8.2           Consent
to Jurisdiction. The Parties hereby submit to the jurisdiction of the state or federal courts sitting in the State of
Delaware over any suit, action, or proceeding arising out of or relating to this Note or any other agreements or instruments
with respect to Holder. The parties hereby waive, to the fullest extent permitted by law, any objection that the parties may
now or hereafter have to the laying of venue of any such suit, action, or proceeding brought in any such court and any claim
that any such suit, action, or proceeding brought in any such court has been brought in an inconvenient forum. A final,
non-appealable judgment in any such suit, action, or proceeding brought in any such courts will be conclusive and binding
upon the parties, and may be enforced in any court in which the applicable party is subject to jurisdiction by a suit upon
such judgment, provided that service, .91 process is effected upon the applicable party as provided in this Note or as
otherwise permitted by applicable law.

 

8.3           Waiver
of Jury Trial. THE PARTIES WAIVE ANY RIGHTS THEY MAY HAVE TO A JURY TRIAL OF ANY CLAIM OR CAUSE
OF ACTION ARISING OUT OF THIS AGREEMENT _OR ANY DEALINGS BETWEEN THE PARTIES RELATING TO THE SUBJECT MATTER OF THIS NOTE. THE
SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE
TO THE SUBJECT MATTER OF THE LOAN OR THIS NOTE, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS, AND ALL OTHER COMMON
LAW AND STATUTORY CLAIMS. THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED
EITHER ORALLY OR IN WRITING, AND THIS WAIVER WILL APPLY TQ ANY SUBSEQUENT AMENDMENTS,SUPPLEMENTS OR MODIFICATIONS TO THIS LOAN
OR THIS NOTE OR TO ANY OTHER DOCUMENT OR AGREEMENT RELATING TO THE LOAN OR THIS NOTE.

 

    	 	4	 

     

    

 

8.4           Service
of Process. The parties hereby consent to process being served in any suit, action, or proceeding instituted in connection
with this Note by delivery of a copy thereof by certified mail, postage prepaid, return receipt requested, and/or by delivery
of a copy thereof to a registered agent of the party.

 

SECTION 9. MAKER’S REPRESENTATIONS AND WARRANTIES. 

 

The
Maker represents and warrants the following:

 

9.1           Organization,
Good Standing and Qualification. The Maker is a corporation duly organized, validly existing and in good standing under
the laws of the State of Delaware in the United States, and has all requisite corporate power and authority to carry on its
business. The Maker is duly qualified to transact business and is in good standing in each jurisdiction in which the failure
so to qualify would have a material adverse effect on its business, properties, operations, prospects or condition (financial
or otherwise).

 

9.2           Authorization.
The execution, delivery and performance by the Maker of this Note have been duly authorized by all requisite action by Maker,
if any, in accordance with Delaware law. This Note is a valid and binding obligation of Maker, enforceable against Maker in accordance
with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, or other laws of general application
affecting enforcements of creditors’ rights or general principles of equity.

 

9.3           No
Conflicts. The execution, delivery and performance of this Note and compliance with the provisions hereof by Maker will not,
to the knowledge of Maker, (a) violate any provision of any law, statute, rule or regulation applicable to Maker or any order,
judgment or decree of any court, arbitrator, administrative agency or other governmental body applicable to Maker or any of its
assets or (b) conflict with or result in any material breach of any of the terms or conditions of any agreement or instrument
to which Maker is a party, or give rise to any right of termination, cancellation or acceleration under any such agreement or
instrument, or result in the creation of any lien or other enceibrance upon any of the material assets of Maker.

 

SECTION 10. HOLDER’S REPRESENTATIONS AND WARRANTIES 

 

10.1         Accredited
Investor. Holder hereby represents and warrants that Holder has substantial experience in evaluating and investing in securities,
and is capable of evaluating the merits and risks of its loan to Maker under this Note and any investment in Conversion Shares,
and has the capacity to protect its own interests. Holder is an “accredited investor” within the meaning of Regulation
D under the Securities Act.

 

10.2          Investment Purpose.
This Note is being made for business and investment purposes.

 

SECTION 11. REPLACEMENT OF NOTE.

 

Upon receipt by Maker of reasonable evidence
of the loss, theft, destruction, or mutilation of this Note, Maker will deliver a new Note containing the same terms and conditions
in lieu of this Note. Any Note delivered in accordance with the provisions of this Section 10 will be dated as of the date of this
Note.

 

    	 	5	 

     

    

 

SECTION 12. MISCELLANEOUS.

 

12.1         Notices.
All notices, demands and requests of any kind to be delivered to any party in connection with this Note will be in writing and
will be deemed to be effective upon delivery if (i) personally delivered, (ii) sent by facsimile or en-pil with confirmed
delivery, (iii) sent by nationally or internationally recognized overnight cornier, or (iv)’ sent by registered or certified mail,
return receipt requested and postage prepaid to such address as the party to whom notice is to be given may have furnished to the
other parties hereto.

 

12.2         Parties In
Interest; Assignment. This Note will bind and inure to the benefit of Holder, Maker and their respective successors and permitted
assigns. Maker will not transfer or assign this Note without the prior written consent of Holder. Holder may transfer and assign
this note without the prior consent of Maker.

 

12.3         Severability.
If one or more provisions of this Note are held to be unenforceable under applicable law, then (i) such provision will be excluded
from this Note, (ii) the balance of the Note will be interpreted as if such provision were so excluded, (iii) the balance of the
Note will be enforceable in accordance with its terms, and (iv) the parties will negotiate in good faith to amend or add to the
provisions of this Note to effectuate as nearly as reasonably practicable, and as nearly as permitted under applicable law, the
original intent of the parties with respect to the provision excluded.

 

12.4         Amendments.
No provision of this Note may be amended or waived without the express written consent of both Maker and Holder, provided, however,
that Holder may waive any provision hereof that inures to the benefit of Holder without the prior written consent of Maker.

 

12.5         Governing Law.
This Note will be governed by and construed in accordance with the laws of the State of Delaware, other than any rules relating
to choice of law.

 

12.6         Counterparts.
This Note may be executed ,and delivered in any number of counterparts, each of which is an original and which, together,’
have the same effect as if each party had signed the same document.

 

12.7         Nature of Obligation.
This Note is being made for business and investment purposes and not for household or other purposes.

 

12.8.        Entire Agreement.
This Note contains the entire understanding of the parties with respect to the subject matter hereof and supersedes all .prior
agreements and understandings among the parties with respect thereto.

 

[SIGNATURES ON FOLLOWING PAGE]

 

    	 	6	 

     

    

 

IN WITNESS
WHEREOF, Maker has caused this Note to be duly executed by its duly authorized person(s) as of the date first written above.

 

	NORTHWEST BIOTHERAPEUTICS, INC.

	 	LINDA F. POWERS
	(MAKER)	 	(HOLDER) 4
	 	 	 	 	 
	By:	/s/  Leslie J. Goldman	 	By:	/s/  Linda F. Powers
	Name:   	Leslie J. Goldman	 	 	 
	Title:	Senior Vice President	 	 	 

 

    	 	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]